Newsfeeds Archive - Spark Newswire

3 minute read

Initial Clinical Data Reported From Immutep’s Efti Combined With Radiotherapy And Checkpoint Inhibitor From Phase II Trial In Soft Tissue Sarcoma

May 2, 8:07 AM

Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six patients treated have very good,

IMMP

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

April 24, 12:31 PM

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 27.8% to $0.58 during Wednesday’s regular session. The company’s market…

ADXN

2 minute read

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

By Vandana Singh

April 24, 10:43 AM

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.

IMMP

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

April 24, 8:06 AM

Gainers Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday’s pre-market session. The market value of their…

ADXN

3 minute read

Immutep Appoints Leading Research Institute To Conduct First-in-Human Phase I Study Of IMP761

By Benzinga Newsdesk

April 18, 8:07 AM

Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune

IMMP

3 minute read

First Patient Dosed In Trial Evaluating Efti And The Anti-PD-L1 Therapy BAVENCIO In Metastatic Urothelial Cancer

By Benzinga Newsdesk

January 4, 9:17 AM

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first

IMMP

1 minute read

News

Immutep Receives A$2.6 Million R&D Tax Incentive From French Government

By Benzinga Newsdesk

December 7, 9:16 AM

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it

IMMP

2 minute read

Immutep Announces Site Expansion For INSIGHT-003 Phase I Trial

By Benzinga Newsdesk

November 22, 9:03 AM

IMMP

1 minute read

Immutep Quarterly Activities Report Q1 FY24; With A Cash And Cash Equivalent Balance As At 30 September 2023 Of Approximately $110.1M

By Benzinga Newsdesk

October 31, 8:07 AM

FINANCIAL SUMMARYImmutep continued to prudently manage its cashflow over the first quarter of the new financial year (Q1 FY24), while strategically investing into clinical trial programs for efti.With a cash and cash

IMMP

1 minute read

News

Immutep Receives ~AUD$1.13M R&D Tax Incentive

By Benzinga Newsdesk

October 25, 8:19 AM

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or the "Company"), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Gover

IMMP